ATE388237T1 - Dendritische zellhybride - Google Patents

Dendritische zellhybride

Info

Publication number
ATE388237T1
ATE388237T1 AT98918140T AT98918140T ATE388237T1 AT E388237 T1 ATE388237 T1 AT E388237T1 AT 98918140 T AT98918140 T AT 98918140T AT 98918140 T AT98918140 T AT 98918140T AT E388237 T1 ATE388237 T1 AT E388237T1
Authority
AT
Austria
Prior art keywords
dendritic cell
cell hybrids
methods
dendritic
compositions
Prior art date
Application number
AT98918140T
Other languages
English (en)
Inventor
Jianlin Gong
Donald Kufe
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE388237T1 publication Critical patent/ATE388237T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Photovoltaic Devices (AREA)
AT98918140T 1997-04-15 1998-04-15 Dendritische zellhybride ATE388237T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4360997P 1997-04-15 1997-04-15

Publications (1)

Publication Number Publication Date
ATE388237T1 true ATE388237T1 (de) 2008-03-15

Family

ID=21928022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98918140T ATE388237T1 (de) 1997-04-15 1998-04-15 Dendritische zellhybride

Country Status (8)

Country Link
US (1) US6652848B1 (de)
EP (1) EP1007720B1 (de)
JP (2) JP2002501377A (de)
AT (1) ATE388237T1 (de)
AU (1) AU744042B2 (de)
CA (1) CA2286873C (de)
DE (1) DE69839215T2 (de)
WO (1) WO1998046785A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273753B2 (en) * 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US20050169898A1 (en) 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
AU2001238236B2 (en) * 1997-04-15 2007-02-15 Dana-Farber Cancer Institute, Inc. Cytotoxic t lymphocytes activated by dendritic cell hybrids
EP1071436A4 (de) * 1998-01-26 2003-08-27 Dana Farber Cancer Inst Inc Hybride immun-effektorzellen
US6389455B1 (en) * 1998-09-22 2002-05-14 Richard C. Fuisz Method and apparatus for bouncing electronic messages
WO2000057705A1 (en) * 1999-03-31 2000-10-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
WO2001029193A2 (de) * 1999-10-22 2001-04-26 Peter Leskovar Zellkonstrukte, die für die immuntherapie geeignet sind, deren herstellung und verwendung
KR100363587B1 (ko) * 1999-11-12 2002-12-06 이시우 대식세포와 종양세포의 융합에 의한 항종양 세포성 치료제
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US20070212338A1 (en) * 2000-01-11 2007-09-13 Greenville Hospital System Hybrid cells
US20090087450A1 (en) * 2000-01-11 2009-04-02 Greenville Hospital System Combination therapy of hybrid cells with BCG injection for treating Cancer Patients
EP1541675A3 (de) * 2000-01-11 2007-08-08 Greenville Hospital System Aus Antigene presentierenden Zellen erhärtlich Zellhybride
CN1427889B (zh) 2000-01-11 2011-06-29 格林维尔医院系统公司 由抗原提呈细胞可获得的杂交细胞
ATE374244T1 (de) * 2000-02-11 2007-10-15 Dana Farber Cancer Inst Inc Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
DE10009030A1 (de) * 2000-02-27 2001-09-20 Univ Eberhard Karls Impfstoff
WO2001062902A1 (en) * 2000-02-27 2001-08-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Hybrid cell vaccines
DE10024384A1 (de) * 2000-05-17 2001-11-29 Mack Gerd R Herstellung von dendritischen Zellen aus Rückenmarkstammzellen
AU2599002A (en) * 2000-10-20 2002-04-29 Tsuneya Ohno Fusion cells and cytokine compositions for treatment of disease
DE10139428A1 (de) * 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050180951A1 (en) * 2004-02-12 2005-08-18 Tsuneya Ohno Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
JPWO2005083062A1 (ja) * 2004-02-26 2008-01-17 ジェノミディア株式会社 細胞ワクチン
WO2005084387A2 (en) * 2004-03-02 2005-09-15 Tsuneya Ohno Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
EP2630968A1 (de) 2006-06-30 2013-08-28 Baylor Research Institute Mithilfe von GM-CSF und Interfron alpha erzeugte und mit hitzebehandelten und getöteten Krebszellen geladene dendritische Zellen
CN109385400A (zh) * 2017-08-09 2019-02-26 科济生物医药（上海）有限公司 共表达pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
WO2022216942A1 (en) 2021-04-07 2022-10-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348878A (en) 1990-05-10 1994-09-20 Dana-Farber Cancer Institute Class I MHC-restricted T-T hybridomas, and a CD8-transfected BW5147, fusion partner therefor
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
IT1264516B1 (it) 1993-05-31 1996-09-24 Biotop Sas Di Rita Cassarin Cellule dendritiche immortalizzate
CA2172719A1 (en) * 1993-10-01 1995-04-13 Joyce B. Palazzotto Speech transmission adaptor for use with a respirator mask
CA2178950A1 (en) 1993-12-14 1995-06-22 Yajun Guo Tumor cell fusions and methods for use of such tumor cell fusions
JPH10505498A (ja) 1994-09-09 1998-06-02 ザイモジェネティクス，インコーポレイティド 不死化細胞の調製
AU5436796A (en) 1995-03-31 1996-10-16 Catherine Bruyns Dendritic-like cell/tumor cell hybrids and hybridomas for in ducing an anti-tumor response
WO1998017300A1 (en) * 1996-10-25 1998-04-30 Dana-Farber Cancer Institute, Inc. Mucin-mediated immunomodulation
WO2000057705A1 (en) 1999-03-31 2000-10-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens

Also Published As

Publication number Publication date
EP1007720B1 (de) 2008-03-05
JP2002501377A (ja) 2002-01-15
DE69839215D1 (de) 2008-04-17
AU7112098A (en) 1998-11-11
CA2286873A1 (en) 1998-10-22
US6652848B1 (en) 2003-11-25
CA2286873C (en) 2010-07-13
JP2008263997A (ja) 2008-11-06
WO1998046785A1 (en) 1998-10-22
DE69839215T2 (de) 2009-03-19
AU744042B2 (en) 2002-02-14
EP1007720A1 (de) 2000-06-14
EP1007720A4 (de) 2001-10-24

Similar Documents

Publication Publication Date Title
DE69839215D1 (de) Dendritische zellhybride
AP2001002225A0 (en) 1-heterocycle substituted diarylamines.
EP0948073A4 (de) Elektrolytische lösung und vorrichtung zur generierung elektrischer energie mit dieser lösung
ATE234323T1 (de) N6-heterocyclisch substituierte adenosin-derivate
AU2002364935A1 (en) Enhancement of immune responses by 4-1bb-binding agents
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
MX9800125A (es) Nuevas composiciones medicinales estables para generar aerosoles libres de gas propulsor.
DK0842289T3 (da) Homolog rekombination i eukaryote celler med inaktiveret fejlparringsreparation
NZ305799A (en) Cyclic amidino agents useful as nitric oxide synthase inhibitors
DK1025245T3 (da) Hurtig etablering af stabile pattedyrscelelinjer, der producerer höje koncentrationer af rekombinante proteiner
IT1264516B1 (it) Cellule dendritiche immortalizzate
ES2150950T3 (es) Marcado de moleculas utilizando derivados de 2-hidrazinopiridina.
PT1272633E (pt) Composições e métodos para imunoterapia baseada em células dendríticas
ES8305039A1 (es) "metodo de producir nuevas lineas de celulas t humanas".
GB9825096D0 (en) Cells,culture methods and their uses
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
PT1235579E (pt) Composicoes farmaceuticas contendo trimegestona
GB9919409D0 (en) Baculovirus expression system
DE69619808D1 (de) Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän
TW324824B (en) Monocrystalline synchronous DRAM system
AU1337783A (en) New fibrionoltic enzymes
YU45690B (sh) Postopek za pripravo 9-(2-hidroksietoksimetil)-gvanina
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
AU3823601A (en) Cytotoxic t lymphocytes activated by dendritic cell hybrids
HRP20000683B1 (hr) Postupak za dobivanje r-(+)-6-karboksamido-3-n-metilamino-1,2,3,4-tetrahidrokarbazola

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties